FDA Lifts Hold, Allows Phase 2 Trial of KVD824 for HAE to Open

FDA Lifts Hold, Allows Phase 2 Trial of KVD824 for HAE to Open

306219

FDA Lifts Hold, Allows Phase 2 Trial of KVD824 for HAE to Open

The U.S. Food and Drug Administration (FDA) has lifted the hold it had placed on KalVista Pharmaceuticals’ Phase 2 KOMPLETE trial of KVD824 as a treatment to prevent swelling attacks in people with hereditary angioedema (HAE). KalVista said it is working closely with study investigators and clinical sites so that trial activities can get underway as soon as possible. “The execution of KOMPLETE, our Phase 2 clinical trial for KVD824 as a potential oral prophylactic therapy for…

You must be logged in to read/download the full post.